Tumour-associated CD66b(+) neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer

Por Carus, A, Ladekarl, M, Hager, H, Nedergaard, B S, Donskov, F
Publicado em 2013

Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial...

Por Donskov, F, Hokland, M, Marcussen, N, Torp Madsen, H H, von der Maase, H
Publicado em 2006

Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma

Por Jeppesen, A N, Jensen, H K, Donskov, F, Marcussen, N, von der Maase, H
Publicado em 2010

In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma

Por Donskov, F, Marcussen, N, Hokland, M, Fisker, R, Madsen, H H T, von der Maase, H
Publicado em 2004

Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma

Por Donskov, F, Middleton, M, Fode, K, Meldgaard, P, Mansoor, W, Lawrance, J, Thatcher, N, Nellemann, H, von der Maase, H
Publicado em 2005

Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective respon...

Por Donskov, F, Bennedsgaard, K M, von der Maase, H, Marcussen, N, Fisker, R, Jensen, J J, Naredi, P, Hokland, M
Publicado em 2002

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Por Heng, D. Y., MacKenzie, M. J., Vaishampayan, U. N., Bjarnason, G. A., Knox, J. J., Tan, M. H., Wood, L., Wang, Y., Kollmannsberger, C., North, S., Donskov, F., Rini, B. I., Choueiri, T. K.
Publicado em 2012

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Por Heng, D. Y. C., Choueiri, T. K., Rini, B. I., Lee, J., Yuasa, T., Pal, S. K., Srinivas, S., Bjarnason, G. A., Knox, J. J., MacKenzie, M., Vaishampayan, U. N., Tan, M. H., Rha, S. Y., Donskov, F., Agarwal, N., Kollmannsberger, C., North, S., Wood, L. A.
Publicado em 2014

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Por Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C
Publicado em 2014

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Por Motzer, R.J., Tannir, N.M., McDermott, D.F., Frontera, O. Arén, Melichar, B., Choueiri, T.K., Plimack, E.R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C.K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C.H., Tomita, Y., Castellano, D., Rini, B.I., Chen, A.C., Mekan, S., McHenry, M.B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H.J., Escudier, B.
Publicado no N Engl J Med (2018)